ABSTRACT
Recently, there has been an increase in the number of cases of superior vena cava (SVC) syndrome associated with chronic indwelling central venous catheters. Fibrinolytic therapy and endovascular treatment are currently achieving good results. We present a case history of a patient with SVC with a catheter used for chemotherapy, which was successfully treated with catheter-directed (intraclot) infusion thrombolytic therapy with urokinase.
Subject(s)
Catheterization, Central Venous/adverse effects , Fibrinolytic Agents/therapeutic use , Superior Vena Cava Syndrome/drug therapy , Thrombolytic Therapy/methods , Urokinase-Type Plasminogen Activator/therapeutic use , Anticoagulants/administration & dosage , Anticoagulants/therapeutic use , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/radiotherapy , Breast Neoplasms/surgery , Chemotherapy, Adjuvant , Combined Modality Therapy , Coumarins/administration & dosage , Coumarins/therapeutic use , Drug Therapy, Combination , Female , Fibrinolytic Agents/administration & dosage , Humans , Infusions, Intravenous , Mastectomy, Segmental , Methylprednisolone/therapeutic use , Middle Aged , Radiotherapy, Adjuvant , Subclavian Vein , Superior Vena Cava Syndrome/diagnosis , Superior Vena Cava Syndrome/etiology , Urokinase-Type Plasminogen Activator/administration & dosageABSTRACT
Recently, there has been an increase in the number of cases of superior vena cava (SVC) syndrome associated with chronic indwelling central venous catheters. Fibrinolytic therapy and endovascular treatment are currently achieving good results. We present a case history of a patient with SVC with a catheter used for chemotherapy, which was successfully treated with catheter-directed (intraclot) infusion thrombolytic therapy with urokinase (AU)
Subject(s)
Humans , Female , Middle Aged , Catheterization, Central Venous/adverse effects , Fibrinolytic Agents/administration & dosage , Fibrinolytic Agents/therapeutic use , Vena Cava, Superior , Superior Vena Cava Syndrome/diagnosis , Superior Vena Cava Syndrome/drug therapy , Urokinase-Type Plasminogen Activator/administration & dosage , Urokinase-Type Plasminogen Activator/therapeutic use , Anticoagulants/administration & dosage , Anticoagulants/therapeutic use , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/radiotherapy , Breast Neoplasms/surgery , Chemotherapy, Adjuvant , Superior Vena Cava Syndrome/etiologyABSTRACT
INTRODUCTION: Testicular tumors are frequent in young adults, coinciding with incorporation to military service. The present study evaluates the tumor characteristics, time course and results obtained with the treatments used in our center for this type of neoplasms. MATERIAL AND METHODS: A retrospective longitudinal study was conducted in a cohort of 98 patients with an average age of 28.6 years, subjected to orchiectomy for testicular tumors in our center between 1979 and 2004. Data were collected relating to patient age, tumor characteristics, the outcome of treatment, and the course of the disease. RESULTS: The right testicle was affected in 61% (with significant differences versus the left side). The most common histological type corresponded to non-seminomatous germ cell tumors (NSGCTs) (65.3%), followed by pure seminomas (27.6%) and non-germinal cell tumors (NGCs) (7.1%). NSGCT was diagnosed at a significantly younger average age (23.2 years) than the other two tumor types. Stage I was the most frequent presentation (58%). Seminomas presented in stage I significantly more often (80%) than the others tumors. The data collected over the 25-year study period showed no significant variations in tumor characteristics. The log-rank test showed a significant difference in terms of patient survival according to the tumor cell line (p = 0.000) and stage (p = 0.000), except between stages I and II, where no significant differences were observed in terms of survival. CONCLUSIONS: Non-seminomatous germ cell tumors (NSGCTs) are the most frequent testicular tumors in young adults. Most neoplasms are diagnosed in early stages, the prognosis being better in the case of seminomas and tumor stages I and II (AU)
Subject(s)
Humans , Male , Adult , Testicular Neoplasms/mortality , Testicular Neoplasms/pathology , Testicular Neoplasms/therapy , Spain , Retrospective Studies , Hospitals, Military , Treatment OutcomeABSTRACT
We show in this work the experience of "San Carlos" University Hospital, Madrid, about superior vena cava syndrome in the last 5 years, and we make an intensive review of literature. We have documented 14 cases of superior vena cava syndrome in our Hospital, in patients between 20 and 90 years of age (x: 61 years) and sex distribution of males (42.8%) and females (57.2%).
Subject(s)
Superior Vena Cava Syndrome , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Prognosis , Superior Vena Cava Syndrome/diagnosis , Superior Vena Cava Syndrome/etiology , Superior Vena Cava Syndrome/therapyABSTRACT
Presentation of one case of embryonic paratesticular rhabdomyosarcoma in a 19-year old male. Following high inguinal radical orchiectomy, he required hemiscrotectomy, and it was found to be a foreign body granuloma. Prior to staging lymphadenectomy, therapy was complemented with radiotherapy and polychemotherapy according to a VAC protocol. The patient shows clinical remission at two and a half years after being diagnosed and one and a half years after completion of treatment.
